Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of GDC-9545 versus physician's choice endocrine monotherapy in previously treated ER-positive, HER2-negative advanced or metastatic breast cancer
CTR20202301Phase 2Active
- Sponsor
- Roche
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of giredestrant in breast cancer, sponsored by Roche. Started Mar 2021; status: active.
02
Drugs
giredestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20202301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202301.